Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Huang X, Ding Q, Guo H, Gong Y, Zhao J, Zhao M, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L.
Huang X, et al. Among authors: gong y.
Hum Pathol. 2021 Feb;108:42-50. doi: 10.1016/j.humpath.2020.11.004. Epub 2020 Nov 19.
Hum Pathol. 2021.
PMID: 33221342